Why Concordia International Corp. Has Fallen +28% Intraday

What are the reasons behind Concordia International Corp.’s (TSX:CXR)(NYSE:CXRX) plummeting shares?

The Motley Fool

To put it mildly, Concordia International Corp. (TSX:CXR)(NYSE:CXRX) shareholders are not happy. The shares have fallen more than 28% intraday.

Why?

To sum it up, Concordia lowered its revenues and earnings guidance for the year, is changing its CFO, and cut its dividend.

Let’s take a look at its business.

The business

Concordia has a diversified portfolio of branded and generic prescription products. It operates in three business segments, including Concordia International, Concordia North America, and Orphan Drugs.

The Concordia International segment is comprised of Amdipharm Mercury Limited (AMCo), which Concordia acquired mainly through debt in October 2015. AMCo focuses on acquiring, licensing, and developing off-patent prescription medicines that are niche or hard-to-make products.

AMCo’s diversified portfolio consists of branded and generic products that it sells to wholesalers, hospitals, and pharmacies in more than 100 countries.

The Concordia North America segment focuses predominantly on the U.S. pharmaceutical market. Its North American portfolio consists of branded products and authorized generic contracts.

Products include Donnatal, which treats irritable bowel syndrome, Nilandron, which treats metastatic prostate cancer, Lanoxin, which treats mild to moderate heart failure and atrial fibrillation, and more.

Why has it fallen?

There are a number of reasons why the market views Concordia negatively. First, Concordia lowered this year’s guidance for its revenues and earnings.

Specifically, the company lowered its revenues to US$859-888 million from US$1,020-1,060 million. It lowered its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to US$510-540 million from US$610-640 million. This is a 16% decline in revenue and EBITDA using the midpoints.

Second, Concordia’s CFO is changing. Any management change adds another level of uncertainty. CFO Adrian de Saldanha will be leaving the company to pursue other opportunities. However, he will help out in the transition period, while Concordia’s executive vice president, Edward Borkowski, steps up to the role of CFO. As a result, Mr. Borkowski will also step down from his position on the board.

Mr. Borkowski suits the CFO role because he was previously the CFO and executive vice president of Mylan N.V.

During the seven years he was there, he helped lead the company “from a US$900 million revenue U.S.-based firm, to an international leader in generic and branded pharmaceuticals through a number of strategic acquisitions and internally focused development of new products,” according to Concordia’s second-quarter-results announcement. Before joining Concordia, Mr. Borkowski also had experience as the CFO of a generic pharmaceutical company.

Third, Concordia is eliminating its dividend, so the capital may be put to better use; for example, it could be used for value creation or debt repayment. Personally, I think it’d be better for Concordia to pay off its debt first, which brings me to the fourth point.

Concordia targets the year-end net debt/EBITDA to be 6.4 times or lower compared with the first-quarter’s target year-end net debt/EBITDA of approximately 5.5 times. This is a higher debt level than most investors like.

Fifth, about 66% of Concordia’s revenues are generated outside the U.S., so if the U.S. dollar remains strong against other currencies, it’ll translate to lower earnings and revenue for Concordia.

Conclusion

For a stock as volatile and risky as Concordia, a good way to keep investors sane is to start with a small percentage of their holdings in their portfolios (if they invest in it at all). All I can say is try not to be emotional about it. I’m not buying or selling Concordia; I’m employing a wait-and-see attitude until at least some of the reasons that are causing its shares to plummet are somewhat resolved.

Fool contributor Kay Ng owns shares of Concordia International.

More on Investing

man crosses arms and hands to make stop sign
Dividend Stocks

Telus Stock: Buy, Sell, or Hold for 2027?

Telus stock’s recovery remains uncertain amid challenges despite the recent rally triggered by Québecor’s takeover proposal.

Read more »

Business doodle about dividends on chalkboard
Dividend Stocks

BCE vs. Enbridge: Which Stock Offers the More Convincing Dividend Case?

BCE and Enbridge offer similar starting yields. I’d choose the one with a clearer route from operating cash to the…

Read more »

jar with coins and plant
Dividend Stocks

How Much to Invest in TC Energy for $142 a Quarter in Dividends

With predictable cash flows, consistent dividend growth, an attractive yield, and clear growth opportunities, TC Energy is ideal for income-seeking…

Read more »

Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
Tech Stocks

Where Could Celestica Stock Be in 5 Years? What the New Outlook Means

Celestica’s ambitious 2027 outlook and accelerating AI infrastructure demand could fuel its next phase of growth, making its recent stock…

Read more »

man in bowtie poses with abacus
Dividend Stocks

How Much Would You Need in SmartCentres to Collect $250 a Month?

SmartCentres can pay an actual monthly distribution. Reaching $250 from it alone would require nearly $45,000 at recent prices.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Stock Market

One ETF or Several? How to Keep Your Investments as Simple as Possible

Here's how choosing the right mix of ETFs could help you simplify your investments while building long-term wealth.

Read more »

ETFs can contain investments such as stocks
Dividend Stocks

1 Top Dividend ETF to Buy to Generate Passive Income

Vanguard's VDY pays monthly with a 0.22% MER and a 3% yield. See what $20,000 could earn, the bank and…

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

2 of the Best ETFs to Buy Now

Looking for the best ETFs to buy now? Explore how XEQT offers global stock exposure while ZAG adds Canadian bonds…

Read more »